A service-partnership biotechnology company located in Mulhouse (France) since May 2007 and Cambridge (Massachusetts, USA) since January 2012

We provide new solutions to discover new medicines against Alzheimer's and other central nervous system (CNS) diseases by:

• developing breakthrough biosimulation platforms for Memory and other CNS functions
• developing service / partnership with pharma and biotech companies for the optimization of their drug discovery process offering unique opportunity to potential investors for large returns and exciting development perspectives

Rhenovia Pharma is the first CNS pharmaceutical company building its Drug Discovery strategy on modeling and simulation before experimental testing. Biosimulation consists in the use of computational models that provide a dynamic and quantitative description of a number of biological, pathological, and pharmacokinetic processes in order to understand complex biological processes.

Biosimulation is particularly appropriate for use in CNS disease research.

Demonstration in 2 videos:

http://www.industrie.com/it/pharmacie/rhenovia-s-t-imule-les-neurones.9971

Picture: The executive team of Rhenovia